Oral Agents for Advanced Hormone Receptor Positive Breast Cancer

Improve your knowledge of, confidence, and competence in the appropriate use of oral agents for patients with HR-positive, advanced, or metastatic breast cancer during the HOPA Satellite Symposium Pre-Conference, Oral Agents for Advanced Hormone Receptor Positive Breast Cancer, April 12 at 1:00 PM CDT. Hear from panelists as they discuss challenging cases of patients, their guidance on evidence-based treatment choices for patients in the various lines of treatment, and the management of treatment-related severe adverse events in these patients.

Walk away with strategies to manage acquisition of, adherence to, and treatment-related adverse events of oral drug-inclusive treatment regimens as part of a multidisciplinary team.

Leigh Boehmer, PharmD, BCOP, Chief Medical Officer, Association of Community Cancer Centers
Pavani Chalasani MD, MPH, Associate Professor of Medicine, Program Director-Hematology/Oncology Fellowship, University of Arizona Cancer Center
Elizabeth Dow, PharmD, BCOP, BCPS, Clinical Pharmacist, Hematology/Oncology, UW Health
Tammy Smith, MSN, FNP-C, CBCN, Nurse Practitioner, Breast Cancer Medical Oncology, Inova Schar Cancer Institute

• This on-demand session is eligible for 1 CE/CPE accreditation by HOPA. To claim this credit, please click here to take this session.
• This on-demand session is eligible for 1 CME and CNE accreditation by AXIS. To claim this credit, please click here to take this session.

This session is supported by an educational grant from Novartis.